Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 298

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 1
Chunk 298
---
 candidates, their methods of use, and methods of manufacture, any, or all of them may not be subject to effective
patent protection. If any of our products are approved and marketed for an indication for which we do not have an issued patent, our
ability to use our patents to prevent a competitor from commercializing a non-branded version of our commercial products for that non-patented
indication could be significantly impaired or even eliminated.

Publication
of information related to our product candidates by us, or others may prevent us from obtaining or enforcing patents relating to these
products and product candidates. Furthermore, others may independently develop similar products, may duplicate our products, or may design
around our patent rights. In addition, any of our issued patents may be opposed and/or declared invalid or unenforceable. If we fail
to adequately protect our intellectual property, we may face competition from companies who attempt to create a generic product to compete
with our product candidates. We may also face competition from companies who develop a substantially similar product to one of our product
candidates that is not covered by any of our patents.

Many
companies have encountered significant problems in protecting, defending and enforcing intellectual property rights in foreign jurisdictions.
The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other
intellectual property rights, particularly those relating to pharmaceuticals, which could make it difficult for us to stop the infringement
of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent
rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business.

Currently,
we do not own the rights to the intellectual property and technology that will be used to commercially develop our initial product candidate,
Telomir-1. MIRALOGX, which is a separate intellectual property development company owned by a trust established by the Company’s
founder, holds the patent rights to Telomir-1, which are currently comprised of a pending non-provisional patent application. Pending
the issuance of the non-provisional patent application, we will have an exclusive, license from MIRALOGX to develop and commercialize
Telomir-1 in the U.S. for human and non-human applications. The term of the license will continue through the date of the expiration
of the last-to-expire licensed patent or, if later, the date of the expiration of the last strategic partnership/sublicensing agreement